MiNK Therapeutics is a biopharmaceutical company developing allogeneic iNKT cell therapies and immune technologies for treatment.
MiNK Therapeutics's investors include National Institute of Allergy and Infectious Diseases, GKCC.
MiNK Therapeutics is headquartered in New York, United States.
MiNK Therapeutics is a biopharmaceutical company developing allogeneic iNKT cell therapies and immune technologies for treatment.
MiNK Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MiNK Therapeutics — Funding & Investors." VCBacked, June 2, 2025, https://www.vcbacked.co/company/mink-therapeutics. Accessed September 29, 2026.
VCBacked. (2025). MiNK Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/mink-therapeutics
{{cite web |title=MiNK Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mink-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated